Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 4 | 4 | PSYCHIATRY//PSYCHOLOGY, CLINICAL//PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | 1867560 |
| 128 | 3 | AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION//HEALTH LITERACY//INFORMED CONSENT | 68930 |
| 2219 | 2 | GENERIC DRUGS//ORPHAN DRUGS//GENERIC SUBSTITUTION | 5103 |
| 31066 | 1 | MCLAUGHLIN ROTMAN GLOBAL HLTH//BIOTECH AND PHARMA INDUSTRIES//ESRC INNOGEN | 173 |
Terms with highest relevance score |
| rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|---|
| 1 | MCLAUGHLIN ROTMAN GLOBAL HLTH | address | 461810 | 10% | 15% | 17 |
| 2 | BIOTECH AND PHARMA INDUSTRIES | authKW | 364358 | 1% | 100% | 2 |
| 3 | ESRC INNOGEN | address | 245926 | 5% | 15% | 9 |
| 4 | AC 2592 | authKW | 182179 | 1% | 100% | 1 |
| 5 | ACT 280778 | authKW | 182179 | 1% | 100% | 1 |
| 6 | ADX 415 | authKW | 182179 | 1% | 100% | 1 |
| 7 | ANTIHYPERTENSIVES NICOX 1 | authKW | 182179 | 1% | 100% | 1 |
| 8 | ANTIHYPERTENSIVES NICOX 2 | authKW | 182179 | 1% | 100% | 1 |
| 9 | ATHEROSCLEROSIS THERAPY LILLY 2 | authKW | 182179 | 1% | 100% | 1 |
| 10 | AZD 0837 | authKW | 182179 | 1% | 100% | 1 |
Web of Science journal categories |
| chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | Integrative & Complementary Medicine | 626 | 8% | 0% | 13 |
| 2 | Management | 555 | 13% | 0% | 22 |
| 3 | Health Policy & Services | 283 | 7% | 0% | 12 |
| 4 | Planning & Development | 190 | 5% | 0% | 8 |
| 5 | Biotechnology & Applied Microbiology | 156 | 14% | 0% | 24 |
| 6 | Business | 94 | 5% | 0% | 8 |
| 7 | Health Care Sciences & Services | 85 | 5% | 0% | 9 |
| 8 | Pharmacology & Pharmacy | 84 | 15% | 0% | 26 |
| 9 | Multidisciplinary Sciences | 41 | 3% | 0% | 5 |
| 10 | Public, Environmental & Occupational Health | 25 | 6% | 0% | 11 |
Address terms |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | MCLAUGHLIN ROTMAN GLOBAL HLTH | 461810 | 10% | 15% | 17 |
| 2 | ESRC INNOGEN | 245926 | 5% | 15% | 9 |
| 3 | CLIN CANC INFORMAT | 182179 | 1% | 100% | 1 |
| 4 | DISTINGUISHED INVESTIGATORS CANADIAN HLTH RE | 182179 | 1% | 100% | 1 |
| 5 | GRP ESTUDOS BIOQUIM FARMACOL TOXICOL MOL | 182179 | 1% | 100% | 1 |
| 6 | KNOWLEDGE OURCES | 182179 | 1% | 100% | 1 |
| 7 | MCLAUGHLIN ROTMAN GLOBAL HLTHPROGRAM LIFE SC | 182179 | 1% | 100% | 1 |
| 8 | NCL INNOVAT | 182179 | 1% | 100% | 1 |
| 9 | ORG TECHNOL MANAGEMENT ENTREPRENEURSHIP OT | 182179 | 1% | 100% | 1 |
| 10 | PAX HERBAL CLIN | 182179 | 1% | 100% | 1 |
Journals |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | TECHNOLOGY ANALYSIS & STRATEGIC MANAGEMENT | 45073 | 9% | 2% | 16 |
| 2 | JOURNAL OF INTELLECTUAL PROPERTY RIGHTS | 16897 | 2% | 3% | 3 |
| 3 | BMC INTERNATIONAL HEALTH AND HUMAN RIGHTS | 14091 | 3% | 2% | 5 |
| 4 | BIOTECHNOLOGY LAW REPORT | 4822 | 1% | 1% | 2 |
| 5 | NATURE BIOTECHNOLOGY | 3314 | 4% | 0% | 7 |
| 6 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2941 | 3% | 0% | 6 |
| 7 | AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES | 2765 | 2% | 0% | 4 |
| 8 | FORBES | 1950 | 1% | 1% | 2 |
| 9 | SCIENCE AND PUBLIC POLICY | 1556 | 1% | 0% | 2 |
| 10 | GLOBALIZATION AND HEALTH | 1456 | 1% | 0% | 2 |
Author Key Words |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | BIOTECH AND PHARMA INDUSTRIES | 364358 | 1% | 100% | 2 | Search BIOTECH+AND+PHARMA+INDUSTRIES | Search BIOTECH+AND+PHARMA+INDUSTRIES |
| 2 | AC 2592 | 182179 | 1% | 100% | 1 | Search AC+2592 | Search AC+2592 |
| 3 | ACT 280778 | 182179 | 1% | 100% | 1 | Search ACT+280778 | Search ACT+280778 |
| 4 | ADX 415 | 182179 | 1% | 100% | 1 | Search ADX+415 | Search ADX+415 |
| 5 | ANTIHYPERTENSIVES NICOX 1 | 182179 | 1% | 100% | 1 | Search ANTIHYPERTENSIVES+NICOX+1 | Search ANTIHYPERTENSIVES+NICOX+1 |
| 6 | ANTIHYPERTENSIVES NICOX 2 | 182179 | 1% | 100% | 1 | Search ANTIHYPERTENSIVES+NICOX+2 | Search ANTIHYPERTENSIVES+NICOX+2 |
| 7 | ATHEROSCLEROSIS THERAPY LILLY 2 | 182179 | 1% | 100% | 1 | Search ATHEROSCLEROSIS+THERAPY+LILLY+2 | Search ATHEROSCLEROSIS+THERAPY+LILLY+2 |
| 8 | AZD 0837 | 182179 | 1% | 100% | 1 | Search AZD+0837 | Search AZD+0837 |
| 9 | AZD 1305 | 182179 | 1% | 100% | 1 | Search AZD+1305 | Search AZD+1305 |
| 10 | AZD 2927 | 182179 | 1% | 100% | 1 | Search AZD+2927 | Search AZD+2927 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |